MedDataX Logo

Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.

NCT ID: NCT05153200

Last Updated: 2021-12-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-31

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this phase 4 pilot study is to assess 1-year recruitment, and 6-month retention rates for participants with rheumatoid arthritis (RA) recruited to this study. Secondarily, we aim to study the difference in multifaceted pain scoring and Musculoskeletal Ultrasound (MSK-US)-detected synovitis between those treated with Upadacitinib vs Adalimumab.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a 26-week phase 4 randomized, single-blind, parallel-group, active treatment-controlled pilot/feasibility study designed to primary assess recruitment and retention rates and to secondarily assess the efficacy of Upadacitinib vs Adalimumab in controlling multiple measures of pain and MSK-US-detected synovitis in those with Active Rheumatoid Arthritis.

Participants with active RA despite combination conventional synthetic Disease Modifying Antirheumatic Drugs (csDMARD), alternative biologic DMARD (bDMARD), or alternative targeted synthetic DMARD (tsDMARD) will be randomized in a 1:1 ratio to:

* Upadacitinib(Rinvoq) 15 mg orally (po) daily or
* Comparison Group: Adalimumab(Idacio) 40 mg subcutaneously (sc) every other week Baseline methotrexate may be continued if patient is receiving at time of study enrollment.

At 1 year after study initiation, recruitment rate over the first year will be measured and rate of 6-month participant retention will also be measured.

At baseline, 1 month, 3 months, and 6 months after initiation of study drug, disease activity, pain, MSK-US synovitis, and other patient important outcomes will be collected.

The study will be completed after 6-months of follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors
MSK-US assessors will be blinded to treatment allocation, pain scores, and disease activity measures.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Upadacitinib(Rinvoq)

Upadacitinib(Rinvoq) 15 mg po daily

Group Type EXPERIMENTAL

Upadacitinib

Intervention Type DRUG

15 mg po daily

Adalimumab(Idacio)

Group Type ACTIVE_COMPARATOR

Adalimumab

Intervention Type DRUG

40 mg sc every other week

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Upadacitinib

15 mg po daily

Intervention Type DRUG

Adalimumab

40 mg sc every other week

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Rinvoq Idacio

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of RA based on ACR/EULAR 2020 Classification Criteria
* Moderate-to-high disease activity according to clinical disease activity indices
* Referred to the biologics clinic (The Ottawa Hospital Arthritis Centre) by their primary rheumatologist who practices within the division following decision to escalate to, or switch between, advanced therapy.

Exclusion Criteria

* Any contraindication to initiation of either Upadacitinib or Adalimumab
* Unable to come to follow-up at 1, 3, and 6 months
* Current or planned (within 6 months) pregnancy or breastfeeding
* Inability to give informed consent
* Inability to communicate verbal or written responses to pain questionnaires
* Intraarticular steroid injections if done within 30 days of first visit
* Initiation of study intervention prior to baseline assessment
* Previous use of either study drug
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Ottawa Hospital

OTHER

Sponsor Role collaborator

University of Ottawa

OTHER

Sponsor Role collaborator

Ottawa Hospital Research Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Elliot P Hepworth, MD

Role: CONTACT

Phone: 613-738-8400

Email: [email protected]

Sibel Z Aydin, MD

Role: CONTACT

Phone: (613) 738-8400

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20210654-01H

Identifier Type: -

Identifier Source: org_study_id